Drug Trial Radar · NCT02500706
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Jun 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,108
Actual
Start
May 4, 2016
Primary completion
Jul 17, 2017
Study completion Aug 16, 2017
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspartDrug
Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
insulin aspartDrug
Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
insulin degludecDrug
Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c 26 Weeks After RandomisationTime frame: Week 0, week 26
Locations
152 sites in 13 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Tucson, Arizona
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Encino, California
Novo Nordisk Investigational Site
Escondido, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Fullerton, California
Novo Nordisk Investigational Site
Huntington Beach, California
Novo Nordisk Investigational Site
Monterey, California
Novo Nordisk Investigational Site
Newport Beach, California
Novo Nordisk Investigational Site
Santa Barbara, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Golden, Colorado
Novo Nordisk Investigational Site
Palm Harbor, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Idaho Falls, Idaho
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Lexington, Kentucky
Novo Nordisk Investigational Site
Louisville, Kentucky
Novo Nordisk Investigational Site
Baltimore, Maryland
Novo Nordisk Investigational Site
Rockville, Maryland
Novo Nordisk Investigational Site
Flint, Michigan
Novo Nordisk Investigational Site
Kalamazoo, Michigan
Novo Nordisk Investigational Site
Minneapolis, Minnesota
Novo Nordisk Investigational Site
Jefferson City, Missouri
Novo Nordisk Investigational Site
Las Vegas, Nevada
Novo Nordisk Investigational Site
Nashua, New Hampshire
Novo Nordisk Investigational Site
Hamilton, New Jersey
Novo Nordisk Investigational Site
Lawrenceville, New Jersey
Novo Nordisk Investigational Site
Albuquerque, New Mexico
Novo Nordisk Investigational Site
Albany, New York
Novo Nordisk Investigational Site
Rochester, New York
Novo Nordisk Investigational Site
Chapel Hill, North Carolina
Novo Nordisk Investigational Site
Greenville, North Carolina
Novo Nordisk Investigational Site
Wilmington, North Carolina
Novo Nordisk Investigational Site
Bend, Oregon
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania
Novo Nordisk Investigational Site
Chattanooga, Tennessee
Novo Nordisk Investigational Site
Amarillo, Texas
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.